Trial · NCT03468426
Participant flow33
How many started, completed or left each group, period by period.
1 to 20 of 33
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part 1 - BI 836880 360 mg | 3 | |
| Overall Study | STARTED | Part 1 - BI 836880 500 mg | 3 | |
| Overall Study | STARTED | Part 1 - BI 836880 720 mg | 8 | |
| Overall Study | STARTED | Part 2 - Cohort A, 2nd line NSCLC | 42 | |
| Overall Study | STARTED | Part 2 - Cohort B, 3rd line NSCLC | 40 | |
| Overall Study | STARTED | Part 2 - Cohort C, SCLC | 31 | |
| Overall Study | STARTED | Part 2 - Cohort D, glioblastoma | 31 | |
| Overall Study | STARTED | Part 2 - Cohort E, Melanoma | 32 | |
| Overall Study | STARTED | Part 2 - Cohort F, 2nd line Hepatocellular Carcinoma | 30 | |
| Overall Study | STARTED | Part 2 - Cohort G, 1st line Hepatocellular Carcinoma (HCC) | 31 | |
| Overall Study | STARTED | Part 2 - Cohort H, 2nd line HCC - atezolizumab in combination with bevacizumab failures | 1 | |
| Overall Study | COMPLETED | Part 1 - BI 836880 360 mg | 0 | |
| Overall Study | COMPLETED | Part 1 - BI 836880 500 mg | 1 | |
| Overall Study | COMPLETED | Part 1 - BI 836880 720 mg | 0 | |
| Overall Study | COMPLETED | Part 2 - Cohort A, 2nd line NSCLC | 6 | |
| Overall Study | COMPLETED | Part 2 - Cohort B, 3rd line NSCLC | 5 | |
| Overall Study | COMPLETED | Part 2 - Cohort C, SCLC | 3 | |
| Overall Study | COMPLETED | Part 2 - Cohort D, glioblastoma | 2 | |
| Overall Study | COMPLETED | Part 2 - Cohort E, Melanoma | 1 | |
| Overall Study | COMPLETED | Part 2 - Cohort F, 2nd line Hepatocellular Carcinoma | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03468426/flow